{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:43:29Z","timestamp":1761709409693},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,11,11]],"date-time":"2017-11-11T00:00:00Z","timestamp":1510358400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Community Ment Health J"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10597-017-0203-y","type":"journal-article","created":{"date-parts":[[2017,11,11]],"date-time":"2017-11-11T02:55:36Z","timestamp":1510368936000},"page":"717-724","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Monitoring and Treating Metabolic Abnormalities in Patients with Early Psychosis Initiated on Antipsychotic Medications"],"prefix":"10.1007","volume":"54","author":[{"given":"Kevin M.","family":"Bozymski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Whitten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley M.","family":"Overley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,11]]},"reference":[{"issue":"Suppl 1","key":"203_CR1","first-page":"S1","volume":"39","author":"American Diabetes Association","year":"2016","unstructured":"American Diabetes Association. (2016). Standards of medical care in diabetes\u20142016. Diabetes Care, 39(Suppl 1), S1\u2013S112.","journal-title":"Diabetes Care"},{"issue":"2","key":"203_CR2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","volume":"272","author":"American Diabetes Association","year":"2004","unstructured":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 272(2), 596\u2013601.","journal-title":"Diabetes Care"},{"issue":"6","key":"203_CR3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/eip.12180","volume":"9","author":"S Archie","year":"2015","unstructured":"Archie, S., Zangeneh-Kazemi, A., & Akhtar-Danesh, N. (2015). First-episode affective psychosis and lipid monitoring: Survival analysis of the first abnormal lipid test. Early Intervention in Psychiatry, 9(6), 507\u2013511.","journal-title":"Early Intervention in Psychiatry"},{"key":"203_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/eip.12457","author":"R Balotsev","year":"2017","unstructured":"Balotsev, R., Haring, L., Koido, K., Leping, V., Kriisa, K., Zilmer, M., \u2026 Vasar, E. (2017). Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: A 7-month follow-up study. Early Intervention in Psychiatry. https:\/\/doi.org\/10.1111\/eip.12457 .","journal-title":"Early Intervention in Psychiatry"},{"issue":"1","key":"203_CR5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., \u2026 Schizophrenia Patient Outcomes Research Team (PORT). (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin, 36(1), 71\u201393.","journal-title":"Schizophrenia Bulletin"},{"key":"203_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/eip.12288","author":"R Carney","year":"2015","unstructured":"Carney, R., Bradshaw, T., & Yung, A. R. (2015). Monitoring of physical health in services of young people at ultra-high risk of psychosis. Early Intervention in Psychiatry. https:\/\/doi.org\/10.1111\/eip.12288 .","journal-title":"Early Intervention in Psychiatry"},{"issue":"2\u20133","key":"203_CR7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.schres.2016.01.010","volume":"170","author":"R Carney","year":"2016","unstructured":"Carney, R., Cotter, J., Bradshaw, T., Firth, J., & Yung, A. R. (2016). Cardiometabolic risk factors in young people at ultra-high risk for psychosis: A systematic review and meta-analysis. Schizophrenia Research, 170(2\u20133), 290\u2013300.","journal-title":"Schizophrenia Research"},{"issue":"8","key":"203_CR8","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0269881116645254","volume":"30","author":"SJ Cooper","year":"2016","unstructured":"Cooper, S. J., Reynolds, G. P., Barnes, T. R. E., England, E., Haddad, P. M., Heald, A., \u2026 Smith, J. (2016). BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. Journal of Psychopharmacology, 30(8), 717\u2013748.","journal-title":"Journal of Psychopharmacology"},{"issue":"2","key":"203_CR9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1192\/apt.10.2.107","volume":"10","author":"I Cormac","year":"2004","unstructured":"Cormac, I., Martin, D., & Ferriter, M. (2004). Improving the physical health of long-stay psychiatric in-patients. Advances in Psychiatric Treatment, 10(2), 107\u2013115.","journal-title":"Advances in Psychiatric Treatment"},{"issue":"16","key":"203_CR10","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","volume":"302","author":"CU Correll","year":"2009","unstructured":"Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA: The Journal of the American Medical Association, 302(16), 1765\u20131773.","journal-title":"JAMA: The Journal of the American Medical Association"},{"issue":"12","key":"203_CR11","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","volume":"71","author":"CU Correll","year":"2014","unstructured":"Correll, C. U., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., \u2026 Kane, J. M. (2014). Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: Baseline results from the RAISE-ETP study. JAMA Psychiatry, 71(12), 1350\u20131363.","journal-title":"JAMA Psychiatry"},{"key":"203_CR12","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2017.0034","author":"RO Cotes","year":"2017","unstructured":"Cotes, R. O., Fernandes, N. K., McLaren, J. L., McHugo, G. J., Bartels, S. J., & Brunette, M. F. (2017). Improving cardiometabolic outcomes of children on antipsychotics. Journal of Child and Adolescent Psychopharmacology. https:\/\/doi.org\/10.1089\/cap.2017.0034 .","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"4","key":"203_CR13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1751-7893.2009.00140.x","volume":"3","author":"J Crabb","year":"2009","unstructured":"Crabb, J., McAllister, M., & Blair, A. (2009). Who should swing the stethoscope? An audit of baseline physical examination and blood monitoring on new patients accepted by an early intervention in psychosis team. Early Intervention in Psychiatry, 3(4), 312\u2013316.","journal-title":"Early Intervention in Psychiatry"},{"issue":"3","key":"203_CR14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","volume":"26","author":"M Hert De","year":"2011","unstructured":"De Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011). Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry, 26(3), 144\u2013158.","journal-title":"European Psychiatry"},{"issue":"9","key":"203_CR15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.18553\/jmcp.2015.21.9.769","volume":"21","author":"GA Edelsohn","year":"2015","unstructured":"Edelsohn, G. A., Parthasarathy, M., Terhorst, L., Karpov, I. O., & Schuster, J. (2015). Measurement of metabolic monitoring in youth and adult Medicaid recipients prescribed antipsychotics. Journal of Managed Care and Specialty Pharmacy, 21(9), 769\u2013777.","journal-title":"Journal of Managed Care and Specialty Pharmacy"},{"key":"203_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/eip.12456","author":"C Garcia-Rizo","year":"2017","unstructured":"Garcia-Rizo, C., Casanovas, M., Fernandez-Egea, E., Oliveira, C., Mesequer, A., Cabrera, B., \u2026 Bernardo, M. (2017). Blood cell count in antipsychotic-naive patients with non-affective psychosis. Early Intervention in Psychiatry. https:\/\/doi.org\/10.1111\/eip.12456 .","journal-title":"Early Intervention in Psychiatry"},{"key":"203_CR17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fpsyt.2012.00062","volume":"3","author":"JM Gohlke","year":"2012","unstructured":"Gohlke, J. M., Dhurandhar, E. J., Correll, C. U., Morrato, E. H., Newcomer, J. W., Remington, G., \u2026 Allison, D. B. (2012). Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. Frontiers in Psychiatry, 3, 62.","journal-title":"Frontiers in Psychiatry"},{"issue":"5","key":"203_CR18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/08039488.2010.500397","volume":"64","author":"D Gothefors","year":"2010","unstructured":"Gothefors, D., Adolfsson, R., Attvall, S., Erlinge, D., Jarbin, H., Lindstrom, K., \u2026 Swedish Psychiatric Association. (2010). Swedish clinical guidelines: Prevention and management of metabolic risk in patients with severe psychiatric disorders. Nordic Journal of Psychiatry, 64(5), 294\u2013302.","journal-title":"Nordic Journal of Psychiatry"},{"issue":"6","key":"203_CR19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ahj.2005.02.007","volume":"150","author":"CH Hennekens","year":"2005","unstructured":"Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005). Schizophrenia and increased risks of cardiovascular disease. American Heart Journal, 150(6), 1115\u20131121.","journal-title":"American Heart Journal"},{"key":"203_CR20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2147\/NDT.S119632","volume":"13","author":"HT Horsdal","year":"2017","unstructured":"Horsdal, H. T., Benros, M. E., Kohler-Forsberg, O., Krogh, J., & Gasse, C. (2017). Metabolic profile at first-time schizophrenia diagnosis: A population-based cross-sectional study. Neuropsychiatric Disease and Treatment, 13, 621\u2013630.","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"2","key":"203_CR21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., \u2026 Brown, W. V. (2015). National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 \u2013 full report. Journal of Clinical Lipidology, 9(2), 129\u2013169.","journal-title":"Journal of Clinical Lipidology"},{"issue":"5","key":"203_CR22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., \u2026 Ortiz, E. (2014). 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA: The Journal of the American Medical Association, 311(5), 507\u2013520.","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"203_CR23","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m10479","author":"KG Jensen","year":"2017","unstructured":"Jensen, K. G., Correll, C. U., Ruda, D., Klauber, D. G., Stentebjerg-Olesen, M., Fagerlund, B., \u2026 Pagsberg, A. K. (2017). Pretreatment cardiometabolic status in youth with early-onset psychosis: Baseline results from the TEA trial. Journal of Clinical Psychiatry. https:\/\/doi.org\/10.4088\/JCP.15m10479 .","journal-title":"Journal of Clinical Psychiatry"},{"issue":"10","key":"203_CR24","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5694\/j.1326-5377.2004.tb06443.x","volume":"181","author":"TJ Lambert","year":"2004","unstructured":"Lambert, T. J., Chapman, L. H. & Consensus Working Group. (2004). Diabetes, psychotic disorders, and antipsychotic therapy: A consensus statement. Medical Journal of Australia, 181(10), 544\u2013548.","journal-title":"Medical Journal of Australia"},{"key":"203_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.08.034","author":"O Lederman","year":"2017","unstructured":"Lederman, O., Rosenbaum, S., Maloney, C., Curtis, J., & Ward, P. B. (2017). Modifiable cardiometablic risk factors in youth with at-risk mental states: A cross-sectional pilot study. Psychiatry Research. https:\/\/doi.org\/10.1016\/j.psychres.2017.08.034 .","journal-title":"Psychiatry Research"},{"issue":"9831","key":"203_CR26","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(12)60239-6","volume":"379","author":"S Leucht","year":"2012","unstructured":"Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. The Lancet, 379(9831), 2067\u20132071.","journal-title":"The Lancet"},{"issue":"7","key":"203_CR27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","volume":"70","author":"BJ Miller","year":"2011","unstructured":"Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011). Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biological Psychiatry, 70(7), 663\u2013671.","journal-title":"Biological Psychiatry"},{"issue":"1\u20133","key":"203_CR28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.schres.2016.08.032","volume":"178","author":"B Misiak","year":"2016","unstructured":"Misiak, B., Wisniewski, J., Fleszar, M. G., & Frydecka, D. (2016). Alterations in L-arginine metabolism in first-episode schizophrenia patients: Further evidence for early metabolic dysregulation. Schizophrenia Research, 178(1\u20133), 56\u201357.","journal-title":"Schizophrenia Research"},{"issue":"4","key":"203_CR29","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpediatrics.2010.48","volume":"164","author":"EH Morrato","year":"2010","unstructured":"Morrato, E. H., Nicol, G. E., Maahs, D., Druss, B. G., Hartung, D. M., Valuck, R. J., \u2026 Newcomer, J. W. (2010). Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatrics and Adolescent Medicine, 164(4), 344\u2013351.","journal-title":"Archives of Pediatrics and Adolescent Medicine"},{"issue":"7","key":"203_CR30","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1176\/appi.ps.201400413","volume":"66","author":"KT Mueser","year":"2015","unstructured":"Mueser, K. T., Penn, D. L., Addington, J., Brunette, M. F., Gingerich, S., Glynn, S. M., \u2026 Kane, J. M. (2015). The NAVIGATE program for first-episode psychosis: Rationale, overview, and description of psychosocial components. Psychiatric Services, 66(7), 680\u2013690.","journal-title":"Psychiatric Services"},{"issue":"4","key":"203_CR31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/09638237.2015.1057320","volume":"24","author":"J Murray","year":"2015","unstructured":"Murray, J., Baillon, S., Bruce, J., & Velayudhan, L. (2015). A survey of psychiatrists\u2019 attitudes toward the physical examination. Journal of Mental Health, 24(4), 249\u2013254.","journal-title":"Journal of Mental Health"},{"issue":"25","key":"203_CR32","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program","year":"2002","unstructured":"National Cholesterol Education Program. (2002). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final report. Circulation, 106(25), 3143\u20133421.","journal-title":"Circulation"},{"issue":"Suppl 2","key":"203_CR33","first-page":"51S","volume":"6","author":"National Institutes of","year":"1998","unstructured":"National Institutes of Health, & National Heart, Lung, and Blood Institute. (1998). Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: The evidence report. Obesity Research, 6(Suppl 2), 51S\u2013209S.","journal-title":"Obesity Research"},{"issue":"3","key":"203_CR34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/eip.12083","volume":"8","author":"B O\u2019Donoghue","year":"2014","unstructured":"O\u2019Donoghue, B., Schafer, M. R., Becker, J., Papageorgiou, K., & Amminger, G. P. (2014). Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics. Early Intervention in Psychiatry, 8(3), 276\u2013280.","journal-title":"Early Intervention in Psychiatry"},{"issue":"12","key":"203_CR35","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jamapsychiatry.2015.1737","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015). Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry, 72(12), 1172\u20131181.","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"203_CR36","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.4088\/JCP.v68n1113","volume":"68","author":"R Perez-Iglesias","year":"2007","unstructured":"Perez-Iglesias, R., Crespo-Facorro, B., Amado, J. A., Garcia-Unzueta, M. T., Ramirez-Bonilla, M. L., Gonzalez-Blanch, C., \u2026 Vazquez-Barquero, J. L. (2007). A 12-week randomized clinical trial to evaluate metabolic changes in drug-na\u00efve, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. Journal of Clinical Psychiatry, 68(11), 1733\u20131740.","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2\u20133","key":"203_CR37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.schres.2008.09.028","volume":"107","author":"R Perez-Iglesias","year":"2009","unstructured":"Perez-Iglesias, R., Mata, I., Pelayo-Teran, J. M., Amado, J. A., Garcia-Unzueta, M. T., Berja, A., \u2026 Crespo-Facorro, B. (2009). Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-na\u00efve population. Schizophrenia Research, 107(2\u20133), 115\u2013121.","journal-title":"Schizophrenia Research"},{"issue":"3","key":"203_CR38","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.psychres.2015.07.041","volume":"229","author":"P Petrikis","year":"2015","unstructured":"Petrikis, P., Tigas, S., Tzallas, A. T., Papadopoulos, I., Skapinakis, P., & Mavreas, V. (2015). Parameters of glucose and lipid metabolism at the fasted state in drug-na\u00efve first-episode patients with psychosis: Evidence for insulin resistance. Psychiatry Research, 229(3), 901\u2013904.","journal-title":"Psychiatry Research"},{"issue":"3","key":"203_CR39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jamapsychiatry.2016.3803","volume":"74","author":"T Pillinger","year":"2017","unstructured":"Pillinger, T., Beck, K., Gobjila, C., Donocik, J. G., Jauhar, S., & Howes, O. D. (2017). Impaired glucose homeostasis in first-episode schizophrenia: A systematic review and meta-analysis. JAMA Psychiatry, 74(3), 261\u2013269.","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"203_CR40","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/pch\/16.9.581","volume":"16","author":"T Pringsheim","year":"2011","unstructured":"Pringsheim, T., Panagiotopoulos, C., Davidson, J., Ho, J. & Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group. (2011). Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatrics and Child Health, 16(9), 581\u2013589.","journal-title":"Paediatrics and Child Health"},{"issue":"1\u20133","key":"203_CR41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.schres.2008.01.004","volume":"101","author":"S Saddichha","year":"2008","unstructured":"Saddichha, S., Manjunatha, N., Ameen, S., & Akhtar, S. (2008). Metabolic syndrome in first episode schizophrenia: A randomized double-blind controlled, short-term prospective study. Schizophrenia Research, 101(1\u20133), 266\u2013272.","journal-title":"Schizophrenia Research"},{"issue":"8","key":"203_CR42","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1592\/phco.29.8.975","volume":"29","author":"ME Schneiderhan","year":"2009","unstructured":"Schneiderhan, M. E., Batscha, C. L., & Rosen, C. (2009). Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents. Pharmacotherapy, 29(8), 975\u2013987.","journal-title":"Pharmacotherapy"},{"issue":"9","key":"203_CR43","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3109\/00048674.2011.595370","volume":"45","author":"A Thompson","year":"2011","unstructured":"Thompson, A., Hetrick, S. E., Alvarez-Jim\u00e9nez, M., Parker, A. G., Willet, M., Hughes, F., \u2026 McGorry, P. D. (2011). Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis. Australian and New Zealand Journal of Psychiatry, 45(9), 740\u2013748.","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"203_CR44","first-page":"111","volume":"29","author":"V Woo","year":"2005","unstructured":"Woo, V., Harris, S. B., & Houlden, R. L. (2005). Canadian Diabetes Association position paper: Antipsychotic medications and associated risks of weight gain and diabetes. Canadian Journal of Diabetes, 29, 111\u2013112.","journal-title":"Canadian Journal of Diabetes"}],"container-title":["Community Mental Health Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10597-017-0203-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10597-017-0203-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10597-017-0203-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T02:02:50Z","timestamp":1659837770000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10597-017-0203-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,11]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["203"],"URL":"https:\/\/doi.org\/10.1007\/s10597-017-0203-y","relation":{},"ISSN":["0010-3853","1573-2789"],"issn-type":[{"value":"0010-3853","type":"print"},{"value":"1573-2789","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,11]]}}}